Helsinki-based healthtech startup Gosta Labs has closed an oversubscribed €7.5 million seed round to accelerate the rollout of its AI operating system for oncology professionals. The round was led by Voima Ventures, with participation from COR Group, the Aho family, Reaktor, and a group of existing and new angel investors. Together with a €1.7 million pre-seed round completed in 2024, the company has now secured close to €10 million to scale its platform globally.
Growing Complexity in Cancer Care
Cancer care is becoming more demanding as the number of patients, tumor types, and treatment options continues to rise worldwide. By 2050, projections suggest that more than 35 million new cancer cases will be diagnosed across more than 100 cancer types, placing immense pressure on healthcare systems and professionals. At the same time, oncologists are spending several hours a day navigating fragmented IT systems, unstructured data, and multidisciplinary decision making, all while facing the need to choose among an ever wider range of personalized therapies.
Gosta Labs’ AI Operating System for Oncology
Gosta Labs is building an oncology-focused AI operating system designed to turn each patient encounter into structured, usable data in real time. The platform summarizes and visualizes the full patient journey, automates large parts of clinical documentation, and captures structured information needed for day to day treatment decisions. It also assesses key clinical parameters along each care pathway and links decisions to international guidelines, supporting faster, more consistent, and higher quality care delivery.
Early Adoption Across Multiple Markets
The company’s AI operating system has already been deployed with leading healthcare providers in Finland, Switzerland, the Baltics, and Australia. These early implementations aim to validate how AI driven documentation and decision support can be embedded into complex oncology workflows without disrupting clinical practice. The new funding will help Gosta Labs deepen these collaborations, expand into new markets, and further develop its medical device grade product and AI foundation.
Real World Evidence from ESMO 2025
First real world results from the Gosta AI Operating System were presented at the ESMO 2025 Congress, one of the foremost global oncology conferences. Data from the study show that the system can generate high quality oncology consultation notes in real time, aligned with institutional standards, while automatically classifying Performance Status and CTCAE toxicity grades. Oncologists using the platform were able to complete documentation for follow up visits in a median time of under two minutes, significantly cutting time spent on paperwork and freeing more time for direct patient care.
Impact on Clinical Workflows
Clinicians involved in the early deployments report that the AI system is already reshaping their day to day workflows. By producing structured and accurate notes instantly, while automatically organizing key clinical parameters, the platform reduces manual data entry and the cognitive load associated with repetitive documentation tasks. According to the study’s lead investigator, documentation time per visit has been reduced by more than two thirds at the participating cancer center, allowing oncologists to focus more on clinical decision making and patient interaction.
Experienced Founders and Leadership Team
Gosta Labs was founded in 2023 by CEO Lauri Sippola and co founder Henri Viertolahti, who previously co founded Kaiku Health, a digital health company acquired by Elekta in 2020. Their new venture draws on years of experience building and scaling regulated digital health solutions across multiple markets, particularly in oncology. The wider leadership team includes Chief Medical Officer Dr. Lionel Hadjadjeba and Chief Operating Officer Reetta Arokoski, both of whom bring decades of experience in oncology, medtech, and the international scaling of cancer care technologies.
Investor Confidence in Applied AI for Healthcare
Lead investor Voima Ventures highlights the combination of proven execution, deep clinical domain expertise, and strong AI capabilities as a key differentiator for Gosta Labs. The firm notes that although AI in healthcare is surrounded by hype, Gosta Labs is already delivering tangible value that resonates with customers and end users. For Gosta Labs, the seed funding validates its strategy of focusing on complex medical specialties like oncology, where documentation burdens are high and the potential impact of AI on workflow efficiency and care quality is substantial.
With its oversubscribed €7.5 million seed round, Gosta Labs is moving quickly to position its AI operating system at the center of oncology workflows in multiple regions. The company plans to use the fresh capital to refine its medical grade AI stack, broaden its clinical evidence base, and scale deployments with oncology teams worldwide. As cancer care grows more complex and data intensive, Gosta Labs aims to ensure that every patient encounter becomes safer, more personalized, and less constrained by administrative work.